ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Lyra Therapeutics Inc

Lyra Therapeutics Inc (LYRA)

6.22
-0.31
(-4.75%)
Closed March 29 04:00PM
6.22
0.00
(0.00%)
After Hours: 06:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
6.22
Bid
4.44
Ask
6.81
Volume
1,154,186
6.20 Day's Range 6.68
1.8906 52 Week Range 6.79
Market Cap
Previous Close
6.53
Open
6.54
Last Trade
1
@
6.5
Last Trade Time
Financial Volume
$ 7,491,734
VWAP
6.4909
Average Volume (3m)
299,511
Shares Outstanding
52,563,127
Dividend Yield
-
PE Ratio
-5.91
Earnings Per Share (EPS)
-1.05
Revenue
1.36M
Net Profit
-55.28M

About Lyra Therapeutics Inc

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precis... Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
1970
Lyra Therapeutics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker LYRA. The last closing price for Lyra Therapeutics was $6.53. Over the last year, Lyra Therapeutics shares have traded in a share price range of $ 1.8906 to $ 6.79.

Lyra Therapeutics currently has 52,563,127 shares outstanding. The market capitalization of Lyra Therapeutics is $326.94 million. Lyra Therapeutics has a price to earnings ratio (PE ratio) of -5.91.

LYRA Latest News

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc...

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   SCHEDULE 13G/A   UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G* (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 1...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934  ...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.142.302631578956.086.795.816484066.26507544CS
40.6511.66965888695.576.795.123673676.00446288CS
121.1221.96078431375.16.794.19012995115.48741114CS
262.3259.48717948723.96.792.52667924.62520879CS
524.16201.9417475732.066.791.89062518344.27635311CS
156-5.78-48.16666666671212.6851.861372605.06278312CS
260-14.78-70.38095238121221.861320046.67680106CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

Your Recent History

Delayed Upgrade Clock